SCHEMBL1099760

SCHEMBL1099760

CCCCN(c1sc2ccccc2c1C)S(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.39
HSD11B1 P28845 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
ESR1 P03372 1/20 0.36
PER2 O15055 1/20 0.36
PTPN1 P18031 1/20 0.35
CNR2 P34972 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CNR1 P21554 1/20 0.34
NR1I2 O75469 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099741 0.82 TRPM8 (0.44) TRPM8HSD11B1ESR1PER2ATM
SCHEMBL1099500 0.80 TRPM8 (0.41) TRPM8HSD11B1HTT
SCHEMBL1099919 0.79 TRPM8 (0.61) TRPM8ESR1SMN1; SMN2
SCHEMBL1098284 0.77 TRPM8 (0.40) TRPM8HSD11B1PER2
SCHEMBL1099518 0.77 TSHR (0.38) TRPM8TDP1ESR1MEN1KMT2A
SCHEMBL1098589 0.77 L3MBTL1 (0.61) TRPM8ESR1CNR2MEN1KMT2A
SCHEMBL1100231 0.76 TRPM8 (0.39) TRPM8HSD11B1PTPN1MEN1KMT2A
SCHEMBL1100720 0.76 ALDH1A1 (0.44) TRPM8HSD11B1CNR2MEN1KMT2A
SCHEMBL12000780 0.76 PRNP (0.41) TRPM8HSD11B1TDP1PTPN1CNR2
SCHEMBL1098743 0.76 PTPN1 (0.38) TDP1ESR1PTPN1CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HSD11B1 4304/4885TDP1 3703/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HSD11B1 4304/4885TDP1 3703/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HSD11B1 4304/4885TDP1 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.